Ibrutinib plus rituximab is superior to FCR in previously untreated cll: results of the Phase III NCRI FLAIR Trial
Hillmen, P. Pitchford, A. Bloor, Adrian Broom, A. Young, M. Kennedy, B. Walewska, R. Furtado, M. Preston, G. Neilson, J. R.
Hillmen, P.
Pitchford, A.
Bloor, Adrian
Broom, A.
Young, M.
Kennedy, B.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J. R.
Citations
Altmetric:
Abstract
Authors
Hillmen, P.
Pitchford, A.
Bloor, Adrian
Broom, A.
Young, M.
Kennedy, B.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J. R.
Pemberton, N.
Sidra, G.
Morley, N.
Cwynarski, K.
Schuh, A.
Forconi, F.
Elmusharaf, N.
Paneesha, S.
Fox, C. P.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
Patten, P. E. M.
Allsup, D.
Munir, T.
Pitchford, A.
Bloor, Adrian
Broom, A.
Young, M.
Kennedy, B.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J. R.
Pemberton, N.
Sidra, G.
Morley, N.
Cwynarski, K.
Schuh, A.
Forconi, F.
Elmusharaf, N.
Paneesha, S.
Fox, C. P.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
Patten, P. E. M.
Allsup, D.
Munir, T.
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398802182.